How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

Group 1 - Kiniksa Pharmaceuticals, Ltd. (KNSA) shares have increased by 15.7% in the past four weeks, closing at $22.61, with a mean price target of$35.86 indicating a potential upside of 58.6% [1] - The average price targets from analysts range from $30 to$40, with a standard deviation of $4.18, suggesting a strong agreement among analysts regarding the stock's potential movement [2] - Analysts have shown a positive trend in earnings estimate revisions, with the Zacks Consensus Estimate for the current year increasing by 186.7% over the past month, indicating strong earnings prospects for KNSA [10][11] Group 2 - KNSA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [11] - While price targets can be misleading, the direction indicated by the consensus price target for KNSA appears to be a useful guide for potential price movement [12] - Analysts' growing optimism regarding KNSA's earnings, reflected in the upward revisions of EPS estimates, correlates strongly with expected near-term stock price movements [9]